2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Adjuvant Therapy: new trials by email Literature Review of Adjuvant Therapy trials Research Report on Adjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor - Breast Cancer, Adjuvant Therapy | Phase 3 | Recruiting | Fudan University | 1903 | 2025-06-15 | 2026-01-21 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo - Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 570 | 2023-03-28 | 2023-09-22 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms (2) · Neoplasms by Site (2) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1) · Thoracic Neoplasms (1)
Anastrozole (1) · Letrozole (1) · Tamoxifen (1) · exemestane (1) · icotinib (1)
Betta Pharmaceuticals Co., Ltd. (1) · Fudan University (1)
China (2)
Shun Lu, M.D. (1)